SEC Form 4 · accession 0002071923-26-000007
Caris Life Sciences, Inc. · CAI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Russel Denton
Officer — See Remarks
Period of report
Sep 22, 2026
Accepted (ET)
Sep 23, 2026 · 5:06 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0002019410
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Sep 22, 2026 | S | 7,500 | $31.8168 | D | 174,855 | D | |
| Common Stock | holding | — | — | — | 9,184 | I | By Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.7750 to $31.8700, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2Includes shares acquired in a non-reportable transaction under the Caris Life Sciences, Inc. 2025 Employee Stock Purchase Plan (a tax-qualified plan) after the date of the reporting person's previous Form 4.
Remarks
Senior Vice President, General Counsel, and Secretary